158 related articles for article (PubMed ID: 4053272)
1. Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).
Reece PA; Stafford I; Russell J; Gill PG
Cancer Chemother Pharmacol; 1985; 15(3):295-9. PubMed ID: 4053272
[TBL] [Abstract][Full Text] [Related]
2. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
J Clin Oncol; 1987 Feb; 5(2):304-9. PubMed ID: 3806171
[TBL] [Abstract][Full Text] [Related]
3. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1989; 23(1):37-40. PubMed ID: 2909288
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
6. Disposition of unchanged cisplatin in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Freeman S
Clin Pharmacol Ther; 1987 Sep; 42(3):320-5. PubMed ID: 3621787
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy.
Goel R; Andrews PA; Pfeifle CE; Abramson IS; Kirmani S; Howell SB
Eur J Cancer; 1990 Jan; 26(1):21-7. PubMed ID: 2156545
[TBL] [Abstract][Full Text] [Related]
8. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).
Dumas M; de Gislain C; d'Athis P; Chadoint-Noudeau V; Escousse A; Guerrin J; Autissier N
Cancer Chemother Pharmacol; 1990; 26(4):278-82. PubMed ID: 2369792
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear kinetics of the thiamine cation in humans: saturation of nonrenal clearance and tubular reabsorption.
Weber W; Nitz M; Looby M
J Pharmacokinet Biopharm; 1990 Dec; 18(6):501-23. PubMed ID: 2280348
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of cis-dichlorodiammineplatinum.
Gormley PE; Bull JM; LeRoy AF; Cysyk R
Clin Pharmacol Ther; 1979 Mar; 25(3):351-7. PubMed ID: 761445
[TBL] [Abstract][Full Text] [Related]
11. Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia.
Gerad H; Egorin MJ; Whitacre M; Van Echo DA; Aisner J
Cancer Chemother Pharmacol; 1983; 11(3):162-6. PubMed ID: 6685578
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.
Jacobs C; Coleman CN; Rich L; Hirst K; Weiner MW
Cancer Res; 1984 Aug; 44(8):3632-5. PubMed ID: 6540140
[TBL] [Abstract][Full Text] [Related]
14. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II).
Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
[TBL] [Abstract][Full Text] [Related]
16. Renal handling of cis-diamminedichloroplatinum(II).
Jacobs C; Kalman SM; Tretton M; Weiner MW
Cancer Treat Rep; 1980; 64(12):1223-6. PubMed ID: 7193518
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
[TBL] [Abstract][Full Text] [Related]
18. A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.
Reece PA; Stafford I; Russell J; Khan M; Gill PG
Cancer Chemother Pharmacol; 1987; 20(1):26-32. PubMed ID: 3621450
[TBL] [Abstract][Full Text] [Related]
19. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
Esposito M; Vannozzi M; Viale M; Pellecchia C; Civalleri D; Gogioso L
Anticancer Res; 1995; 15(6B):2541-7. PubMed ID: 8669820
[TBL] [Abstract][Full Text] [Related]
20. Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
Erlichman C; Soldin SJ; Thiessen JJ; Sturgeon JF; Fine S
Cancer Chemother Pharmacol; 1987; 19(1):75-9. PubMed ID: 3815729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
